Bone disease

Knee x-ray
#Bone disease #Osteoporosis #Therapeutic targets #Tokyo University of Science

New study reveals promising drug target for treating osteoporosis

Researchers have identified a novel target downstream of parathyroid hormone (PTH) signalling that suppresses bone formation in osteoporosis. The PTH-derived peptide teriparatide has demonstrated strong bone promoting effects. However, it is also to known to exert bone-resorbing effects. A new study uncovers a novel… Read More

#News

#Bone disease #Collaboration #Heart disease #mRNA #Oncology #Partnership

This week in drug discovery (20-24 May) 

News round-up for 20-24 May by DDW Senior Digital Content Editor Diana Spencer. The headline news this week emphasises the importance of shared expertise and collaboration, whether that be between nations, companies or research institutions, to enable the greatest advances in drug discovery. The top stories:… Read More

#News

Knee x-ray
#Bone disease #Peptides #Preclinical investigations #University of Birmingham

Peptide shows promise as therapeutic for bone loss disorders

Researchers have shown that a naturally occurring peptide holds promise as a new therapeutic for bone loss disorders and could have advantages over existing drugs. PEPITEM (Peptide Inhibitor of Trans-Endothelial Migration) was first identified in 2015 by University of Birmingham researchers. The latest research… Read More

#News

siRNA
#Bone disease #Preclinical investigations #RNA #siRNA #SiSaf

Positive preclinical data for siRNA therapy for osteopetrosis

RNA therapeutics company SiSaf has published positive safety and efficacy data for its siRNA therapy for Autosomal Dominant Osteopetrosis 2 (ADO2). The data demonstrate that siRNA complexed with SiSaf’s silicon stabilised hybrid lipid nanoparticles (sshLNP) was able to significantly downregulate expression of an ADO2-specific mutant gene. Read More

#News